Biomarkers, Omics and Artificial Intelligence for Early Detection of Pancreatic Cancer.

IF 12.1 1区 医学 Q1 ONCOLOGY Seminars in cancer biology Pub Date : 2025-02-20 DOI:10.1016/j.semcancer.2025.02.009
Kate Murray, Lucy Oldfield, Irena Stefanova, Manuel Gentiluomo, Paolo Aretini, Rachel O'Sullivan, William Greenhalf, Salvatore Paiella, Mateus N Aoki, Aldo Pastore, James Birch-Ford, Bhavana Hemantha Rao, Pinar Uysal-Onganer, Caoimhe M Walsh, George B Hanna, Jagriti Narang, Pradakshina Sharma, Daniele Campa, Cosmeri Rizzato, Andrei Turtoi, Elif Arik Sever, Alessio Felici, Ceren Sucularli, Giulia Peduzzi, Elif Öz, Osman Uğur Sezerman, Robert Van der Meer, Nathan Thompson, Eithne Costello
{"title":"Biomarkers, Omics and Artificial Intelligence for Early Detection of Pancreatic Cancer.","authors":"Kate Murray, Lucy Oldfield, Irena Stefanova, Manuel Gentiluomo, Paolo Aretini, Rachel O'Sullivan, William Greenhalf, Salvatore Paiella, Mateus N Aoki, Aldo Pastore, James Birch-Ford, Bhavana Hemantha Rao, Pinar Uysal-Onganer, Caoimhe M Walsh, George B Hanna, Jagriti Narang, Pradakshina Sharma, Daniele Campa, Cosmeri Rizzato, Andrei Turtoi, Elif Arik Sever, Alessio Felici, Ceren Sucularli, Giulia Peduzzi, Elif Öz, Osman Uğur Sezerman, Robert Van der Meer, Nathan Thompson, Eithne Costello","doi":"10.1016/j.semcancer.2025.02.009","DOIUrl":null,"url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed in its late stages when treatment options are limited. Unlike other common cancers, there are no population-wide screening programmes for PDAC. Thus, early disease detection, although urgently needed, remains elusive. Individuals in certain high-risk groups are, however, offered screening or surveillance. Here we explore advances in understanding high-risk groups for PDAC and efforts to implement biomarker-driven detection of PDAC in these groups. We review current approaches to early detection biomarker development and the use of artificial intelligence as applied to electronic health records (EHRs) and social media. Finally, we address the cost-effectiveness of applying biomarker strategies for early detection of PDAC.</p>","PeriodicalId":21594,"journal":{"name":"Seminars in cancer biology","volume":" ","pages":""},"PeriodicalIF":12.1000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in cancer biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.semcancer.2025.02.009","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed in its late stages when treatment options are limited. Unlike other common cancers, there are no population-wide screening programmes for PDAC. Thus, early disease detection, although urgently needed, remains elusive. Individuals in certain high-risk groups are, however, offered screening or surveillance. Here we explore advances in understanding high-risk groups for PDAC and efforts to implement biomarker-driven detection of PDAC in these groups. We review current approaches to early detection biomarker development and the use of artificial intelligence as applied to electronic health records (EHRs) and social media. Finally, we address the cost-effectiveness of applying biomarker strategies for early detection of PDAC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
生物标记物、Omics 和人工智能用于胰腺癌的早期检测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Seminars in cancer biology
Seminars in cancer biology 医学-肿瘤学
CiteScore
26.80
自引率
4.10%
发文量
347
审稿时长
15.1 weeks
期刊介绍: Seminars in Cancer Biology (YSCBI) is a specialized review journal that focuses on the field of molecular oncology. Its primary objective is to keep scientists up-to-date with the latest developments in this field. The journal adopts a thematic approach, dedicating each issue to an important topic of interest to cancer biologists. These topics cover a range of research areas, including the underlying genetic and molecular causes of cellular transformation and cancer, as well as the molecular basis of potential therapies. To ensure the highest quality and expertise, every issue is supervised by a guest editor or editors who are internationally recognized experts in the respective field. Each issue features approximately eight to twelve authoritative invited reviews that cover various aspects of the chosen subject area. The ultimate goal of each issue of YSCBI is to offer a cohesive, easily comprehensible, and engaging overview of the selected topic. The journal strives to provide scientists with a coordinated and lively examination of the latest developments in the field of molecular oncology.
期刊最新文献
Editorial Board Atrial fibrillation in cancer patients: Epidemiology, identification and management Biomarkers, Omics and Artificial Intelligence for Early Detection of Pancreatic Cancer. Editorial – Hypoxia as a molecular driver of cancer progression Metabolic crosstalk between platelets and cancer: Mechanisms, functions, and therapeutic potential
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1